Seres Therapeutics (MCRB) Receiving Favorable News Coverage, Report Shows

News articles about Seres Therapeutics (NASDAQ:MCRB) have trended positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Seres Therapeutics earned a daily sentiment score of 0.28 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.170556880843 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

A number of research analysts have recently commented on the company. ValuEngine lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. BidaskClub raised Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Wednesday, August 30th. Finally, Canaccord Genuity set a $20.00 target price on Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $18.00.

Shares of Seres Therapeutics (NASDAQ:MCRB) traded up $0.37 during mid-day trading on Friday, reaching $10.34. The company had a trading volume of 191,400 shares, compared to its average volume of 235,793. Seres Therapeutics has a fifty-two week low of $8.85 and a fifty-two week high of $17.42. The company has a quick ratio of 6.86, a current ratio of 6.53 and a debt-to-equity ratio of 0.11.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The business had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $17.29 million. During the same quarter last year, the business posted ($0.46) earnings per share. The company’s quarterly revenue was up 76.9% on a year-over-year basis. sell-side analysts predict that Seres Therapeutics will post -2.37 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/11/12/seres-therapeutics-mcrb-receiving-favorable-news-coverage-report-shows.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Insider Buying and Selling by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply